<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app19.us.archive.org';v.server_ms=1525;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10393?contentType=xml', '20171003010500')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20171003010500/https://www.guideline.gov/summaries/downloadcontent/ngc-10393?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20171003010500/https://www.guideline.gov/summaries/downloadcontent/ngc-10393?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10393?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20171003010500" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930213924/https://www.guideline.gov/summaries/downloadcontent/ngc-10393?contentType=xml" title="30 Sep 2016"><strong>Sep</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 01:05:00 Oct 03, 2017">OCT</td>
		  <td class="f" nowrap="nowrap">Nov</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930213924/https://www.guideline.gov/summaries/downloadcontent/ngc-10393?contentType=xml" title="21:39:24 Sep 30, 2016"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 01:05:00 Oct 03, 2017">03</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930213924/https://www.guideline.gov/summaries/downloadcontent/ngc-10393?contentType=xml" title="30 Sep 2016"><strong>2016</strong></a></td>
		  <td class="c" id="displayYearEl" title="You are here: 01:05:00 Oct 03, 2017">2017</td>
		  <td class="f" nowrap="nowrap">2018</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20171003010500*/https://www.guideline.gov/summaries/downloadcontent/ngc-10393?contentType=xml" title="See a list of every capture for this URL">2 captures</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016 - 03 Oct 2017</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10393?contentType=xml","2017-10-03",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Care of the HIV-exposed infant with indeterminate status.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>New York State Department of Health. Care of the HIV-exposed infant with indeterminate status. New York (NY): New York State Department of Health; 2014 Jan. 15 p.  [28 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The quality of evidence (<strong>I-III</strong>) and strength of recommendation (<strong>A-C</strong>) are defined at the end of the &quot;Major Recommendations&quot; field.</p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Major Recommendations: Care of the HIV-exposed infant with indeterminate status&quot;>
    <tbody>
        <tr>
            <td><strong>Important Notes</strong><br />
            <br />
            The <strong>recommended routine postnatal prophylaxis for all human immunodeficiency virus (HIV)-exposed infants</strong> has changed. The new recommended dosing is as follows:
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>Zidovudine (ZDV) syrup, 4 mg/kg per dose PO given twice daily through 6 weeks of age, started as soon as possible (within 6 hours, and no later than 12 hours of delivery). See table below for dosing for premature infants &amp;lt;35 weeks' gestation. </li>
            </ul>
            <br />
            <strong>Clinical scenarios that warrant supplemental prophylaxis are as follows</strong>:
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>Mother received no antepartum therapy and only intrapartum ZDV </li>
                <li>Mother received no antepartum and no intrapartum prophylaxis </li>
                <li>Mother received antepartum therapy with incomplete (HIV ribonucleic acid [RNA] &amp;gt;1,000 copies/mL) or unknown degree of viral suppression </li>
                <li>Mother has known drug-resistant HIV </li>
            </ul>
            <br />
            The <strong>recommended supplemental postnatal prophylaxis</strong> is as follows:
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>ZDV as above </li>
            </ul>
            <em>plus</em> <br />
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>Nevirapine (NVP) &amp;ndash; 3 doses given in the first week of life (see table below):
                <ul style=&quot;list-style-type: disc;&quot;>
                    <li>12 mg PO per dose if BW &amp;gt;2 kg </li>
                    <li>8 mg PO per dose if BW 1.5&amp;ndash;2 kg </li>
                </ul>
                </li>
            </ul>
            <br />
            When treating <strong>infants born to mothers with known or suspected drug resistance</strong>, clinicians should consult with a pediatric provider who has experience with HIV treatment and management. Whenever possible, consultation should occur <em>before</em> delivery.</td>
        </tr>
    </tbody>
</table>
<p><strong><span style=&quot;text-decoration: underline;&quot;>General Recommendations</span></strong></p>
<p>All human immunodeficiency virus (HIV) infection-exposed infants should receive care from, or in consultation with, a pediatrician experienced with HIV treatment and management. (<strong>AI</strong>)</p>
<p><span style=&quot;text-decoration: underline;&quot;><strong>Newborn Antiretroviral (ARV) Prophylaxis for HIV-exposed Infants</strong></span></p>
<p>Clinicians should administer zidovudine (ZDV) for prevention of mother-to-child-transmission of HIV to all HIV-exposed infants as soon as possible after birth (<strong>AI</strong>):</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>ZDV (4 mg/kg PO twice daily) should be administered as soon as possible after birth, within 6 hours, and no later than 12 hours of delivery (<strong>AII</strong>) </li>
    <li>ZDV prophylaxis should be given for 6 weeks (<strong>AI</strong>); dose adjustments should be made as the infant's weight changes </li>
    <li>Dosing of ZDV prophylaxis should be adjusted for premature infants &amp;lt;35 weeks' gestational age (see table below) (<strong>AII</strong>) </li>
</ul>
<p>Clinicians should administer supplemental ARV prophylaxis as close to the time of birth as possible for the following infants:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Infants born to HIV-infected women who received no antepartum antiretroviral therapy (ART) and only intrapartum ZDV </li>
    <li>Infants born to HIV-infected women who received no antepartum ART and no intrapartum ZDV </li>
    <li>Infants born to HIV-infected women with suboptimal viral load levels (&amp;gt;1,000 copies/mL) (<em>consider</em>) </li>
    <li>Infants born to HIV-infected women with known drug-resistant HIV. </li>
</ul>
<p>The preferred prophylactic regimen includes 6 weeks of daily ZDV <em>plus</em> 3 doses of nevirapine (NVP) administered during the first week of life (at birth, 48 hours after the first dose, and 96 hours after the second dose). See table below for dosing. (<strong>AI</strong>)</p>
<p>Clinicians should consult a pediatric provider who has experience with HIV treatment and management when using combination regimens other than those shown in Table 1 below and should discuss potential risks and benefits with the mother. Whenever possible, consultation should occur <em>before</em> delivery. At each visit, clinicians should:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Educate and demonstrate to the caregiver how to measure and administer the correct ZDV dosage to be given to the infant because the dosage will change as the infant's weight changes </li>
    <li>Recommend and provide infant oral syringes for administering accurate ZDV dosages </li>
    <li>Use vocabulary that caregivers can understand, regardless of educational level, and provide written information that is well organized and easy to understand </li>
    <li>Document in the medical record that administration of the accurate ZDV dosage was discussed with the caregiver </li>
</ul>
<br />
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Key Point&quot;>
    <tbody>
        <tr>
            <td valign=&quot;top&quot;><span style=&quot;text-decoration: underline;&quot;><strong>Key Point</strong></span>:<br />
            <br />
            Birth facilities should routinely stock liquid formulations of ZDV and NVP for immediate use in infants born to HIV-infected mothers, as indicated in table below.</td>
        </tr>
    </tbody>
</table>
<p><strong>Table: Antiretroviral Prophylaxis Regimens to Reduce Mother-to-Child HIV Transmission in HIV-exposed Infants</strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Antiretroviral Prophylaxis Regimens to Reduce Mother-to-Child HIV Transmission in HIV-exposed Infants&quot;>
    <thead>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;3&quot;>Routine Postnatal Prophylaxis for All HIV-exposed Infants</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td valign=&quot;top&quot; colspan=&quot;3&quot;><strong><span style=&quot;text-decoration: underline;&quot;>Full-term Newborn Regimen (&amp;ge;35 weeks' gestation)</span></strong><br />
            Start as soon as possible (within 6 hours, and no later than 12 hours of delivery)
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>ZDV syrup, 4 mg/kg per dose PO given twice daily through 6 weeks of age<sup>a</sup> </li>
            </ul>
            </td>
        </tr>
        <tr>
            <td valign=&quot;top&quot; colspan=&quot;3&quot;><strong><span style=&quot;text-decoration: underline;&quot;>Preterm Newborn Regimen</span></strong><br />
            Start as soon as possible (within 6 hours, and no later than 12 hours of delivery)
            <ul style=&quot;list-style-type: disc;&quot;>
                <li><em>For &amp;ge;30 to &amp;lt;35 weeks' gestation</em>: ZDV 2 mg/kg per dose PO [or 1.5 mg/kg per dose IV] given every 12 hours, then advance to 3 mg/kg/dose (2.3 mg/kg/dose IV) every 12 hours beginning at age 15 days through 6 weeks of age </li>
                <li><em>For &amp;lt;30 weeks' gestation</em>: ZDV 2 mg/kg per dose PO [or 1.5 mg/kg per dose IV] given every 12 hours, then advance to 3 mg/kg/dose (2.3 mg/kg/dose IV) every 12 hours beginning at 4 weeks of age through 6 weeks of age </li>
            </ul>
            </td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;3&quot;><strong>Supplemental Postnatal Antiretroviral Prophylaxis</strong><br />
            (see Table 2 in the original guideline document for infants who should receive supplemental prophylaxis)</td>
        </tr>
        <tr>
            <th valign=&quot;top&quot;>Drugs for Infant</th>
            <th valign=&quot;top&quot;>Dosing</th>
            <th valign=&quot;top&quot;>Duration</th>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>2-drug regimen:<br />
            ZDV + NVP<sup>b</sup></td>
            <td valign=&quot;top&quot;>ZDV: <em>as above</em><br />
            (4 mg/kg per dose PO twice a day)<br />
            <br />
            NVP: 12 mg PO per dose if BW&amp;gt;2kg<br />
            &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;8 mg PO per dose if BW 1.5-2 kg </td>
            <td valign=&quot;top&quot;>Birth through 6 weeks<br />
            3 doses in first week of life:
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>1st dose within first 48 hr of birth </li>
                <li>2nd dose 48 hr after 1st dose </li>
                <li>3rd dose 96 hr after 2nd dose </li>
            </ul>
            </td>
        </tr>
        <tr>
            <td valign=&quot;top&quot; colspan=&quot;3&quot;><span class=&quot;Note&quot;>NVP, nevirapine; HIV, human immunodeficiency virus; IV, intravenous; ZDV, zidovudine.<br />
            <sup>a</sup>If unable to tolerate orally, administer ZDV 3.0 mg/kg per dose IV every 12 hours, started as soon as possible after birth (within 6 hours, and no later than 12 hours of delivery).<br />
            <sup>b</sup>Consultation with a pediatric provider who has experience with HIV treatment and management is advised before administering NVP to neonates who are &amp;lt;1.5 kg or &amp;lt;32 weeks estimated gestational age at birth.</span></td>
        </tr>
    </tbody>
</table>
<p><strong>Newborn Antiretroviral Prophylaxis: Specific Scenarios</strong></p>
<p><em>Infants Born to Mothers Who Received Antepartum Antiretroviral Therapy with Undetectable HIV Viral Load Levels at Delivery</em></p>
<p>All infants whose mothers received antepartum ART with undetectable HIV viral load levels at the time of delivery should be given ZDV for 6 weeks (see table above). (<strong>AI</strong>)</p>
<p><em>Infants Born to Mothers Who Received Only Intrapartum Prophylaxis</em></p>
<p>Infants born to mothers who received only intrapartum ARV drugs should be given ZDV for 6 weeks <em>plus</em> 3 doses of NVP in the first week of life (see table above). (<strong>AI</strong>)</p>
<p><em>Infants Born to Mothers Who Did Not Receive Antepartum or Intrapartum Antiretroviral Drugs</em></p>
<p>All infants whose mothers did not receive antepartum ART or intrapartum ZDV should be given ZDV for 6 weeks plus 3 doses of NVP in the first week of life (see table above). (<strong>AI</strong>)</p>
<p><em>Infants Born to Mothers Who Have Received Antepartum/Intrapartum Antiretroviral Drugs but Have Suboptimal Viral Suppression Near Delivery</em></p>
<p>Providers should consult with a pediatric provider who has experience with HIV treatment and management of HIV-exposed infants to determine whether to use the two-drug regimen of ZDV + NVP (see table above) for infants of mothers with suboptimal viral suppression. (<strong>BIII</strong>)</p>
<p><em>Infants Born to Mothers with Antiretroviral Drug-Resistant Virus</em></p>
<p>Before delivery, clinicians should consult a pediatric provider who has experience with HIV treatment and management when treating infants born to mothers with known or suspected drug resistance. (<strong>BIII</strong>)</p>
<p><strong>Antiretroviral Drug Dosing for Premature Infants</strong></p>
<p>Use of ARV drugs other than ZDV and NVP should be avoided in premature infants (see table above). (<strong>BIII</strong>)</p>
<p>Clinicians should consult a pediatric provider who has experience with HIV treatment and management to determine the optimal regimen when the neonate is at high risk for HIV infection. (<strong>BIII</strong>)</p>
<p>Clinicians should consult with a pediatric provider who has experience with HIV treatment and management before administering NVP to neonates who are &amp;lt;1.5 kg or &amp;lt;32 weeks' estimated gestational age at birth.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Diagnostic Testing</span></strong></p>
<p>New York State Department of Health (NYSDOH) recommends that all New York State (NYS) birth facilities and pediatricians caring for HIV-exposed infants use the Pediatric HIV Testing Services at the <a href=&quot;http://www.wadsworth.org/divisions/infdis/hiv/pedhivtest.html&quot; title=&quot;Wadsworth Center Web site&quot;>Wadsworth Center</a>.</p>
<p>In New York State, HIV qualitative ribonucleic acid (RNA) testing (nucleic acid test or NAT) is recommended for early detection of HIV infection in infants. Testing should be performed at the following ages: (<strong>AII</strong>)</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Within 48 hours of birth (<strong>BIII</strong>) </li>
    <li>At 2 weeks of age (<strong>AII</strong>) </li>
    <li>At 4 to 6 weeks of age (<strong>AII</strong>) </li>
    <li>At 4 to 6 months of age (<strong>AII</strong>) </li>
</ul>
<p>Positive HIV NAT results at any age should be confirmed by repeat testing as soon as possible on a new sample. (<strong>AII</strong>) Two independent positive test results definitively diagnose pediatric HIV infection in HIV-exposed infants and subsequent testing is not necessary.</p>
<p>Once a positive HIV test result is confirmed, the clinician should:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Consult a provider with experience in pediatric HIV care (<strong>AI</strong>) </li>
    <li>Discontinue perinatal prophylactic ZDV, if still being administered (<strong>AI</strong>) </li>
    <li>Evaluate for initiation of combination ART as soon as possible (<strong>AI</strong>) </li>
</ul>
<p>Two negative HIV NAT results, one obtained &amp;ge;4 weeks of age and one obtained &amp;ge;4 months of age, definitively exclude pediatric HIV infection in HIV-exposed infants. (<strong>AII</strong>)</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;><em>Pneumocystis Jirovecii</em> Pneumonia (PCP) Prophylaxis</span></strong></p>
<p>Clinicians should initiate prophylaxis against PCP at 6 weeks of age for all HIV-exposed infants unless HIV diagnostic testing definitively or presumptively excludes HIV infection (see Table 3 in the original guideline document). Prophylaxis should be continued until the diagnosis of HIV infection is presumptively or definitively excluded (see definitions of exclusion below). (<strong>AII</strong>)</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Feeding HIV-exposed Infants</span></strong></p>
<p>In New York State, breastfeeding by HIV-infected women is contraindicated, even when the mother is receiving combination ART. (<strong>AI</strong>)</p>
<p>Clinicians should strongly advise breastfeeding mothers with newly suspected or diagnosed HIV infection to discontinue breastfeeding immediately. Clinicians should consult with a pediatric provider who has experience with HIV treatment and management to determine whether prophylaxis should be given to the infant.</p>
<p>Clinicians should advise HIV-infected women to avoid premasticating food for infants. (<strong>AII</strong>)</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Immunizations</span></strong></p>
<p>Clinicians should follow the Centers for Disease Control and Prevention (CDC) <a href=&quot;http://www.cdc.gov/mmwr/preview/mmwrhtml/su6201a2.htm&quot; title=&quot;MMWR Web site&quot; target=&quot;_blank&quot;>recommended immunization schedules</a> for HIV-exposed and HIV-infected infants.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Frequency of Visits and Long-Term Follow-Up</span></strong></p>
<p>All HIV-exposed infants should receive care from, or in consultation with, a pediatrician experienced with HIV treatment and management by at least 2 weeks of age, and again at 1 month, 2 months, 4 months, and 6 months.</p>
<p>Clinicians should evaluate for potential mitochondrial dysfunction in ARV-exposed children who develop significant organ system abnormalities. (<strong>BIII</strong>)</p>
<p>Clinicians should:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Document <em>in utero</em> exposure to ARV drugs in the patient's permanent medical record (<strong>AIII</strong>) </li>
    <li>Report cases of prenatal exposure to ARV drugs to the <a href=&quot;http://www.apregistry.com/&quot;>Antiretroviral Pregnancy Registry</a> </li>
</ul>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Definitions</span></strong>:</p>
<p><strong>Quality of Evidence for Recommendations</strong></p>
<ol style=&quot;list-style-type: upper-roman;&quot;>
    <li>One or more randomized trials with clinical outcomes and/or validated laboratory endpoints </li>
    <li>One or more well designed, non-randomized trials or observational cohort studies with long-term clinical outcomes </li>
    <li>Expert opinion<strong> </strong></li>
</ol>
<p><strong>Strength of Recommendation</strong></p>
<ol style=&quot;list-style-type: upper-alpha;&quot;>
    <li>Strong recommendation for the statement </li>
    <li>Moderate recommendation for the statement </li>
    <li>Optional recommendation </li>
</ol></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Human immunodeficiency virus (HIV) infection</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Counseling"/>
      <fieldvalue value="Diagnosis"/>
      <fieldvalue value="Prevention"/>
      <fieldvalue value="Screening"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Allergy and Immunology"/>
      <fieldvalue value="Family Practice"/>
      <fieldvalue value="Infectious Diseases"/>
      <fieldvalue value="Internal Medicine"/>
      <fieldvalue value="Obstetrics and Gynecology"/>
      <fieldvalue value="Pediatrics"/>
      <fieldvalue value="Preventive Medicine"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Health Care Providers"/>
      <fieldvalue value="Nurses"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
      <fieldvalue value="Public Health Departments"/>
      <fieldvalue value="Substance Use Disorders Treatment Providers"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To provide guidance for the care of  human immunodeficiency virus (HIV)-exposed infants with indeterminate status</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Infants at risk for developing human immunodeficiency virus (HIV) infection</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Zidovudine (ZDV) for all human immunodeficiency virus (HIV)-exposed infants </li>
    <li>Supplemental antiretroviral (ARV) prophylaxis </li>
    <li>Consultation with pediatric provider
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Education and demonstration of correct ZDV dosage </li>
        <li>Provision of infant oral syringes </li>
        <li>Documentation in medical record </li>
    </ul>
    </li>
    <li>Two-drug regimen of ZDV + nevirapine (NVP) </li>
    <li>HIV qualitative ribonucleic acid (RNA) testing (nucleic acid test [NAT]) </li>
    <li><em>Pneumocystis jirovecii</em> pneumonia (PCP) prophylaxis </li>
    <li>Advising against breast-feeding or premastication of food </li>
    <li>Immunization </li>
    <li>Follow-up care
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Evaluation for potential mitochondrial dysfunction </li>
        <li>Documenting and reporting exposure to ARV drugs </li>
    </ul>
    </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Mother-to-child transmission of human immunodeficiency virus (HIV) </li>
    <li>Drug resistant HIV </li>
    <li><em>Pneumocystis jirovecii</em> pneumonia (PCP) </li>
    <li>Infant anemia </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The National Library of Medicine, PubMed Central, Cochrane library, and Medline databases were searched for the time frame: 1992-2013 (November 2013); most were from 2008 to 2013; very early studies (1992-1999) were cited for historical reasons.</p>
<p>The inclusion criteria used in the searches were: infants born to HIV-infected mothers; specific scenarios for infants born to HIV-infected mothers; maternal receipt of ART; premature infants. The specific search terms used were: HIV-infected infant; infant ARV prophylaxis; mother-to-child HIV transmission; HIV-infected pregnant women; intrapartum ZDV; HIV RNA viral load; pneumocystis jirovecii pneumonia (PCP); breastfeeding; infant HIV diagnostic testing; infant anemia.</p>
<p>The literature was identified by the author of the draft guideline, and by the co-chairs of the committee in conjunction with program staff. All members of the committee submitted relevant literature to program staff and the author for review for the guideline revision.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Expert Consensus (Committee)"/>
      <fieldvalue value="Weighting According to a Rating Scheme (Scheme Given)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Quality of Evidence for Recommendation</strong></p>
<ol style=&quot;list-style-type: upper-roman;&quot;>
    <li>One or more randomized trials with clinical outcomes and/or validated laboratory endpoints </li>
    <li>One or more well-designed, non-randomized trials or observational cohort studies with long-term clinical outcomes </li>
    <li>Expert opinion </li>
</ol></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>AIDS Institute clinical guidelines are developed by distinguished committees of clinicians and others with extensive experience providing care to people with HIV infection. Committees* meet regularly to assess current recommendations and to write and update guidelines in accordance with newly emerging clinical and research developments.</p>
<p>The Committees* rely on evidence to the extent possible in formulating recommendations. When data from randomized clinical trials are not available, Committees rely on developing guidelines based on consensus, balancing the use of new information with sound clinical judgment that results in recommendations that are in the best interest of patients.</p>
<p>*Current committees include:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Medical Care Criteria Committee </li>
    <li>Committee for the Care of Children and Adolescents with HIV Infection </li>
    <li>Dental Standards of Care Committee </li>
    <li>Mental Health Guidelines Committee </li>
    <li>Committee for the Care of Women with HIV Infection </li>
    <li>Committee for the Care of Substance Users with HIV Infection </li>
    <li>Physician's Prevention Advisory Committee </li>
    <li>Pharmacy Advisory Committee </li>
</ul>
<p>The Perinatal Committee, composed of Pediatricians and Obstetrician-Gynecologists, determined that a guideline was needed that would address care of infants born to mothers with human immunodeficiency virus (HIV) infection. One expert clinician authored the guideline. The committee reviewed the guideline draft and made recommendations to it. The committee convened on August 27, 2012 and May 20, 2013 by conference calls.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Strength of Recommendation</strong></p>
<ol style=&quot;list-style-type: upper-alpha;&quot;>
    <li>Strong recommendation for the statement </li>
    <li>Moderate recommendation for the statement </li>
    <li>Optional recommendation </li>
</ol></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="External Peer Review"/>
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>All guidelines developed by the Committee are externally peer reviewed by at least two experts in that particular area of patient care, which ensures depth and quality of the guidelines.</p>
<p>The guideline draft is peer reviewed by 2 experts outside of the committee; the author incorporates any comments from the peer reviewers and the guideline is again reviewed by the Committee. Once the revision is accepted by the committee, the guideline was reviewed by an internal New York State approval process. Any recommended changes are discussed with the author and the Committee to reach consensus, if needed.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of supporting evidence is identified and graded for selected recommendations (see the &quot;Major Recommendations&quot; field).</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Appropriate care of  human immunodeficiency virus (HIV)-exposed infants with indeterminate status</p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Toxicities from nevirapine (NVP) in the infant are rare but have included severe and potentially life-threatening rash and hepatic toxicity. Toxicities are much more common with NVP dosing for chronic infection than with the three-dose prophylactic regimen recommended for some neonates. For infants who receive NVP as prophylaxis but still become infected, resistance to NVP can occur. </li>
    <li>Anemia has been associated with the use of zidovudine (ZDV); therefore, some experts recommend obtaining a complete blood count (CBC) and differential prior to initiating ZDV. </li>
</ul>"/>
    </field>
  </section>
  <section secid="430" ordby="800" name="Contraindications">
    <field fieldid="144" ordby="805" id="431" name="Contraindications" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>In New York State, breastfeeding by human immunodeficiency virus (HIV)-infected women is contraindicated, even when the mother is receiving combination antiretroviral therapy (ART) </li>
    <li>The use of lopinavir-ritonavir in infants under 2 weeks of age is contraindicated due to toxicity </li>
</ul>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>When formulating guidelines for a disease as complex and fluid as human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), it is impossible to anticipate every scenario. It is expected that in specific situations, there will be valid exceptions to the approaches offered in these guidelines and sound reason to deviate from the recommendations provided within.</p></div>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The AIDS Institute's Office of the Medical Director directly oversees the development, publication, dissemination and implementation of clinical practice guidelines, in collaboration with The Johns Hopkins University, Division of Infectious Diseases. These guidelines address the medical management of adults, adolescents and children with human immunodeficiency virus (HIV) infection; primary and secondary prevention in medical settings; and include informational brochures for care providers and the public.</p>
<p><strong>Guidelines Dissemination</strong></p>
<p>Guidelines are disseminated to clinicians, support service providers, and consumers through mass mailings and numerous AIDS Institute-sponsored educational programs. Distribution methods include the HIV Clinical Resource website, the Clinical Education Initiative (CEI), the AIDS Educational Training Centers (AETC), and the HIV/AIDS Materials Initiative. Printed copies of clinical guidelines are available for order from the New York State Department of Health (NYSDOH) Distribution Center.</p>
<p><strong>Guidelines Implementation</strong></p>
<p>The HIV Clinical Guidelines Program works with other programs in the AIDS Institute to promote adoption of guidelines. Clinicians, for example, are targeted through the CEI and the AETC. The CEI provides tailored educational programming on site for health care providers on important topics in HIV care, including those addressed by the HIV Clinical Guidelines Program. The AETC provides conferences, grand rounds and other programs that cover topics contained in AIDS Institute guidelines.</p>
<p>Support service providers are targeted through the HIV Education and Training initiative which provides training on important HIV topics to non-physician health and human services providers. Education is carried out across the State as well as through video conferencing and audio conferencing.</p>
<p>The HIV Clinical Guidelines Program also works in a coordinated manner with the HIV Quality of Care Program to promote implementation of HIV guidelines in New York State. By developing quality indicators based on the guidelines, the AIDS Institute has created a mechanism for measurement of performance that allows providers and consumers to know to what extent specific guidelines have been implemented.</p>
<p>Finally, best practices booklets are developed through the HIV Clinical Guidelines Program. These contain practical solutions to common problems related to access, delivery or coordination of care, in an effort to ensure that HIV guidelines are implemented and that patients receive the highest level of HIV care possible.</p></div>"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Living with Illness"/>
      <fieldvalue value="Staying Healthy"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Patient-centeredness"/>
      <fieldvalue value="Safety"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>New York State Department of Health. Care of the HIV-exposed infant with indeterminate status. New York (NY): New York State Department of Health; 2014 Jan. 15 p.  [28 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2014 Jan"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="New York State Department of Health - State/Local Government Agency [U.S.]"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>New York State Department of Health</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Perinatal Transmission Committee</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Committee Members</em>: Elaine J Abrams, MD, Columbia University College of Physicians and Surgeons, New York, New York; Mark D Foca, MD, Children's Hospital of New York, New York, New York; Howard Minkoff, MD, Maimonides Medical Center, Brooklyn, New York; Renee Samelson, MD, MPH, Albany Medical Center, Albany, New York; Geoffrey A Weinberg, MD, University of Rochester School of Medicine and Dentistry, Rochester, New York; Andrew A Wiznia, MD, Jacobi Medical Center, Bronx, New York; Rodney L Wright, MD, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York</p>
<p><em>AIDS Institute Staff</em>: Barbara L Warren, BSN, MPH, PNP, New York State Department of Health AIDS Institute, Albany, New York</p>
<p><em>AIDS Institute Staff Liaison</em>: Gina M Brown, MD, National Institutes of Health, Bethesda, Maryland</p>
<p><em>AIDS Institute Staff Physician</em>: Charles J Gonzalez, MD, New York State Department of Health AIDS Institute, New York, New York</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available from the <a href=&quot;http://www.hivguidelines.org/clinical-guidelines/infants-children/care-of-the-hiv-exposed-infant-with-indeterminate-status/&quot; title=&quot;New York State Department of Health AIDS Institute Web site&quot;>New York State Department of Health AIDS Institute Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on August 18, 2014.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is copyrighted by the guideline developer. See the <a href=&quot;http://www.hivguidelines.org/terms-of-usage/&quot; title=&quot;New York State Department of Health AIDS Institute Web site&quot;>New York State Department of Health AIDS Institute Web site</a> for terms of use.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 01:05:00 Oct 03, 2017 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 00:05:57 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 95.143 (3)
  esindex: 0.008
  captures_list: 114.13
  CDXLines.iter: 15.006 (3)
  PetaboxLoader3.datanode: 47.143 (4)
  exclusion.robots: 0.286
  exclusion.robots.policy: 0.272
  RedisCDXSource: 0.749
  PetaboxLoader3.resolve: 1395.953 (2)
  load_resource: 1384.104
-->